The FDA granted guidance on June 27, 2025, allowing outpatient setting for clinical trials involving Lipocine in the United States.
1 report, 0 independent
Updated Jun 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted guidance on June 27, 2025, allowing outpatient setting for clinical trials involving Lipocine in the United States.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Lipocine's study followed FDA feedback regarding its clinical trials.Sub-event
- FDA approved outpatient setting for Lipocine's clinical trials.
Keep exploring
The entities involved
-
Lipocine (United States)
company in Salt Lake City, United States
Nothing else this week.
- FDA
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval expands patient access to therapies for ACCORD.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- The FDA has begun to regulate the market for obesity medications, reflecting a broader trend in pharmaceutical oversight.
Coverage
Newest first; wire copies grouped- Unknown outlet